Crawford Fund Management LLC Has $8.49 Million Stock Position in United Therapeutics Co. (NASDAQ:UTHR)

Crawford Fund Management LLC decreased its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR) by 29.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 23,692 shares of the biotechnology company’s stock after selling 9,908 shares during the period. United Therapeutics comprises approximately 1.8% of Crawford Fund Management LLC’s holdings, making the stock its 2nd largest position. Crawford Fund Management LLC owned about 0.05% of United Therapeutics worth $8,490,000 as of its most recent SEC filing.

A number of other hedge funds have also recently modified their holdings of the business. Renaissance Technologies LLC lifted its stake in shares of United Therapeutics by 1.1% during the 2nd quarter. Renaissance Technologies LLC now owns 2,174,692 shares of the biotechnology company’s stock valued at $692,748,000 after buying an additional 22,978 shares in the last quarter. FMR LLC lifted its stake in United Therapeutics by 41.1% in the 3rd quarter. FMR LLC now owns 1,077,628 shares of the biotechnology company’s stock worth $386,168,000 after purchasing an additional 314,004 shares in the last quarter. LSV Asset Management lifted its stake in United Therapeutics by 82.5% in the 2nd quarter. LSV Asset Management now owns 966,370 shares of the biotechnology company’s stock worth $307,837,000 after purchasing an additional 436,851 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in United Therapeutics by 4.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 585,969 shares of the biotechnology company’s stock worth $186,656,000 after purchasing an additional 22,683 shares in the last quarter. Finally, Pacer Advisors Inc. lifted its stake in United Therapeutics by 0.9% in the 3rd quarter. Pacer Advisors Inc. now owns 566,703 shares of the biotechnology company’s stock worth $203,078,000 after purchasing an additional 4,869 shares in the last quarter. Institutional investors own 94.08% of the company’s stock.

Analyst Ratings Changes

Several brokerages have commented on UTHR. LADENBURG THALM/SH SH boosted their price target on shares of United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. TD Cowen increased their price target on shares of United Therapeutics from $350.00 to $400.00 and gave the company a “buy” rating in a report on Monday, October 21st. HC Wainwright raised their price objective on shares of United Therapeutics from $400.00 to $425.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. Wells Fargo & Company raised their price objective on shares of United Therapeutics from $350.00 to $380.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 20th. Finally, Bank of America decreased their price target on shares of United Therapeutics from $303.00 to $280.00 and set an “underperform” rating for the company in a research note on Thursday, August 1st. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, United Therapeutics has an average rating of “Moderate Buy” and an average price target of $370.86.

Insider Activity at United Therapeutics

In other United Therapeutics news, Director Nilda Mesa sold 224 shares of the stock in a transaction on Friday, November 8th. The shares were sold at an average price of $412.28, for a total transaction of $92,350.72. Following the transaction, the director now directly owns 5,783 shares of the company’s stock, valued at $2,384,215.24. This trade represents a 3.73 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO James Edgemond sold 7,785 shares of the company’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $362.37, for a total transaction of $2,821,050.45. Following the transaction, the chief financial officer now owns 2,615 shares of the company’s stock, valued at approximately $947,597.55. This trade represents a 74.86 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 127,227 shares of company stock worth $47,398,820 in the last 90 days. Corporate insiders own 11.90% of the company’s stock.

United Therapeutics Price Performance

NASDAQ:UTHR opened at $378.13 on Friday. The company’s fifty day moving average price is $366.89 and its 200-day moving average price is $334.15. United Therapeutics Co. has a 1-year low of $208.62 and a 1-year high of $417.82. The firm has a market capitalization of $16.88 billion, a P/E ratio of 16.61, a PEG ratio of 1.10 and a beta of 0.56.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, October 30th. The biotechnology company reported $6.39 EPS for the quarter, topping the consensus estimate of $6.16 by $0.23. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The firm had revenue of $748.90 million for the quarter, compared to analyst estimates of $722.62 million. During the same period last year, the company earned $5.38 earnings per share. United Therapeutics’s revenue for the quarter was up 22.9% compared to the same quarter last year. Equities analysts anticipate that United Therapeutics Co. will post 25.22 EPS for the current fiscal year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.